Analysts’ Weekly Ratings Changes for Amgen (AMGN)

Several analysts have recently updated their ratings and price targets for Amgen (NASDAQ: AMGN):

• 2/12/2025 – Amgen had its “hold” rating reaffirmed by analysts at UBS Group AG.
• 2/10/2025 – Amgen had its price target raised by analysts at Piper Sandler from $310.00 to $329.00. They now have an “overweight” rating on the stock.
• 2/6/2025 – Amgen had its price target raised by analysts at Bank of America Co. from $256.00 to $275.00. They now have an “underperform” rating on the stock.
• 2/5/2025 – Amgen had its “neutral” rating reaffirmed by analysts at Citigroup Inc..
• 2/5/2025 – Amgen had its “equal weight” rating reaffirmed by analysts at Wells Fargo & Company.
• 1/28/2025 – Amgen had its price target lowered by analysts at Citigroup Inc. from $310.00 to $295.00. They now have a “neutral” rating on the stock.
• 1/24/2025 – Amgen had its “outperform” rating reaffirmed by analysts at Royal Bank of Canada. They now have a $324.00 price target on the stock.
• 1/10/2025 – Amgen had its price target lowered by analysts at Wells Fargo & Company from $335.00 to $280.00. They now have an “equal weight” rating on the stock.
• 1/8/2025 – Amgen had its price target lowered by analysts at Truist Financial Co. from $333.00 to $298.00. They now have a “hold” rating on the stock.
• 1/2/2025 – Amgen had its price target lowered by analysts at Piper Sandler from $344.00 to $310.00. They now have an “overweight” rating on the stock.
• 1/2/2025 – Amgen had its “overweight” rating reaffirmed by analysts at Piper Sandler Companies. They now have a $310.00 price target on the stock.

Amgen Price Performance

Shares of Amgen stock traded up $6.61 during trading on Monday, hitting $309.62. 2,354,822 shares of the company were exchanged, compared to its average volume of 3,099,726. The stock has a market capitalization of $166.33 billion, a price-to-earnings ratio of 41.01, a P/E/G ratio of 2.58 and a beta of 0.56. The firm has a 50 day moving average price of $276.27 and a 200 day moving average price of $300.31. Amgen Inc. has a fifty-two week low of $253.30 and a fifty-two week high of $346.85. The company has a quick ratio of 0.95, a current ratio of 1.26 and a debt-to-equity ratio of 9.62.

Amgen (NASDAQ:AMGN) last posted its earnings results on Tuesday, February 4th. The medical research company reported $5.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.04 by $0.27. Amgen had a net margin of 12.24% and a return on equity of 176.32%. On average, equities analysts expect that Amgen Inc. will post 20.6 earnings per share for the current fiscal year.

Amgen Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, February 14th will be issued a $2.38 dividend. This is an increase from Amgen’s previous quarterly dividend of $2.25. The ex-dividend date of this dividend is Friday, February 14th. This represents a $9.52 annualized dividend and a dividend yield of 3.07%. Amgen’s dividend payout ratio (DPR) is 126.09%.

Insider Buying and Selling

In other news, EVP Jonathan P. Graham sold 25,045 shares of the stock in a transaction that occurred on Friday, February 7th. The shares were sold at an average price of $293.12, for a total value of $7,341,190.40. Following the completion of the transaction, the executive vice president now directly owns 28,987 shares in the company, valued at $8,496,669.44. This trade represents a 46.35 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Nancy A. Grygiel sold 1,589 shares of the firm’s stock in a transaction that occurred on Wednesday, February 5th. The stock was sold at an average price of $304.47, for a total transaction of $483,802.83. Following the sale, the senior vice president now owns 7,210 shares of the company’s stock, valued at $2,195,228.70. The trade was a 18.06 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 69,341 shares of company stock worth $20,644,335 in the last three months. 0.69% of the stock is owned by insiders.

Hedge Funds Weigh In On Amgen

Institutional investors have recently bought and sold shares of the stock. Lansing Street Advisors increased its holdings in Amgen by 1.3% in the 3rd quarter. Lansing Street Advisors now owns 2,582 shares of the medical research company’s stock valued at $832,000 after buying an additional 32 shares during the period. Unionview LLC boosted its position in Amgen by 3.8% in the 3rd quarter. Unionview LLC now owns 876 shares of the medical research company’s stock valued at $282,000 after buying an additional 32 shares during the last quarter. AM Investment Strategies LLC lifted its holdings in Amgen by 0.4% in the third quarter. AM Investment Strategies LLC now owns 7,471 shares of the medical research company’s stock valued at $2,407,000 after buying an additional 33 shares during the period. Avidian Wealth Enterprises LLC grew its stake in shares of Amgen by 0.6% during the third quarter. Avidian Wealth Enterprises LLC now owns 5,863 shares of the medical research company’s stock worth $1,889,000 after purchasing an additional 33 shares during the period. Finally, Beacon Financial Advisory LLC increased its stake in shares of Amgen by 4.6% in the 3rd quarter. Beacon Financial Advisory LLC now owns 769 shares of the medical research company’s stock valued at $248,000 after acquiring an additional 34 shares during the last quarter. 76.50% of the stock is currently owned by institutional investors.

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.